fda compounding semaglutide warning letters september 2025 Warns Novo Nordisk on Unreported Deaths Article: Brazilian Clinics and the

LaFemina J, Qin L-X, Moraco NH, Antonescu CR, Fields RC, Crago AM, et al

Here is what caught researchers off guard: liraglutide, dulaglutide, and exenatide showed no statistically significant increase in hair loss reports at all

Versus semaglutide (GLP-1 mono-agonist) : considerable gap

Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell | Bulletin of Experimental Biology and Medicine n.d

doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026 Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026 DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2026, and provided a business update